Tirzepatide is a dual gip/glp-1 receptor agonist with a development status of "fda-approved (branded forms)". The Institute rates the strength of its published evidence as strong. A dual-incretin agonist targeting both GIP and GLP-1 receptors, with weight-reduction results exceeding single-agonist therapies in head-to-head trials.
Commercial availability of Tirzepatide continues to run ahead of its regulatory status. That is the recurring structural feature of this market: demand arrives when trial data is published, and supply arrives from channels that answer to nobody in particular.
Our position on developments like this is consistent. We report what changed, we test what is being sold, and we decline to speculate about what a regulator will do next.
The Institute has independently tested 20 Tirzepatide samples from 13 companies. 95% met their label claims on purity and content. Measured purity ranged from 96.9% to 99.2%, averaging 98.3%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
